Professor in Medicine-Hematology/Oncology and Preventive Medicine
Oncology
Dr. Raymond C. Bergan, MD
|
|
Give Review
Raymond C. Bergan, MD practices Oncology. He attended SUNY Upstate Medical University. Raymond Bergan is a published doctor as well. He has 60 publications published. The latest was: Pharmacokinetics of thalidomide in an elderly prostate cancer population. He accepts all Medicare patients.
Publications
- How do antisense oligodeoxynucleotides inhibit the growth of chronic myelogenous Leukemia cells?
- Effect of over-expression of bacterial ribonuclease H on the utility of antisense MYC oligodeoxynucleotides in the monocytic Leukemia cell line U937.
- Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy.
- Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure.
- Genistein-stimulated adherence of prostate Cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin.
- Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging.
- Genistein-induced apoptosis of prostate Cancer cells is preceded by a specific decrease in focal adhesion kinase activity.
- Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate Cancer: simultaneous antiandrogen withdrawal and prior a...
- Pharmacokinetics of thalidomide in an elderly prostate Cancer population.
- Improved intracellular delivery of oligonucleotides by square wave electroporation.
- Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
- In vitro models of Prostate apoptosis: clusterin as an antiapoptotic mediator.
- A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
- Antisense efficacy : site-restricted in vivo and ex vivo models.
- Labeling TiO2 nanoparticles with dyes for optical fluorescence microscopy and determination of TiO2-DNA nanoconjugate stability.
- Methyl selenocysteine: single-dose pharmacokinetics in men.
- A phase II study of single agent bortezomib in patients with metastatic breast Cancer: a single institution experience.
- Gene expression profiling of renal medullary carcinoma: potential clinical relevance.
- Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with Cancer.
- p38 MAP kinase modulates Smad-dependent changes in human Prostate cell adhesion.
- An analysis of gene array data related to cell adhesion and prostate Cancer.
- Some aspects of analysis of gene array data.
- Over expression of endoglin in human prostate Cancer suppresses cell detachment, migration and invasion.
- Renal medullary carcinoma and ABL gene amplification.
- Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human Prostate epithelial cells.
- Safety and efficacy of weekly oral oltipraz in Chronic smokers.
- Genistein induces phenotypic reversion of endoglin deficiency in human prostate Cancer cells.
- Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial.
- The ninth annual american association of Cancer research international conference on frontiers in Cancer prevention research.
- Endoglin regulates Cancer-stromal cell interactions in prostate tumors.
- Endoglin suppresses human prostate Cancer metastasis.
- Inhibition of Cancer cell invasion and metastasis by genistein.
- Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance ...
- Dietary genistein inhibits metastasis of human prostate Cancer in mice.
- Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human Prostate carcinoma PC3-M cells.
- The methodology used to measure differential gene expression affects the outcome.
- Associations of serum carotenoid levels with serum insulin-like growth factor-i and insulin-like growth factor binding protein-3 levels in black men and white men.
- Endoglin phosphorylation by ALK2 contributes to the regulation of prostate Cancer cell migration.
- MEK4 function, genistein treatment, and invasion of human prostate Cancer cells.
- Genistein inhibits matrix metalloproteinase type 2 activation and prostate Cancer cell invasion by blocking the transforming growth factor beta-mediated activation of ...
- Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate Cancer.
- MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate Cancer.
- Endoglin inhibits prostate Cancer motility via activation of the ALK2-Smad1 pathway.
- Characterization of a method for profiling gene expression in cells recovered from intact human Prostate tissue using RNA linear amplification.
- Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation.
- Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate Cancer.
- A simple analysis of gene expression and variability in gene arrays based on repeated observations.
- A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate Cancer.
- Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in Leukemia cells.
- Growth inhibition of chronic myelogenous Leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity.
- Prostate Cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1).
- A phase II study of 5-aza-2''deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate Cancer.
- Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate Cancer.
- Ex vivo bone marrow purging with oligonucleotides.
- Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate Cancer.
- Antitumor activity of suramin in hormone-refractory prostate Cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variab...
- Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides.
- Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate Cancer.
- Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Schools
Upstate Medical University College of Health Professions
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
National Institutes of Health Clinical Center -
SUNY Upstate Medical University
Hospital
-
Northwestern Memorial Hospital -
Lurie Children's Hospital of Chicago
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871569640 |
| Last Name Of The Provider | BERGAN |
| First Name Of The Provider | RAYMOND |
| View All |
Similar Doctors
|
|
Dr. Nicklas R. Pfanzelter, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey C. Cilley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shuo Ma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margaret C. Telfer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Blase N. Polite, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James Mulshine, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Irum H. Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Peace, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sigmund A. Weitzman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine A. Bueschel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Oana C. Danciu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melinda K. Gordon, MD |